Cure Ventures — Full Portfolio
27 tracked investments · listed companies and verified rows first
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Chief Scientific Advisor and Director)Cam Gallagher(Executive Officer, Director)inJohn Maroney(Executive Officer, Director)
BoardZachary Collins(Executive Officer)inSteve Tregay(Director)in
Board seatAnnie Mitsak· per SEC Form D
Co-investorsMission Bay CapitalMission Biocapital
BiotechBoston, US
Ronald D. Seidel, III(Executive Officer, Director)
BoardCameron Gallagher(Director)Rodolfo Chaparro(Director)Andrew King(Executive Officer)in
Board seatLou Tartaglia· per SEC Form D
BiotechCambridge, US
Peter Fuhrken(Director)Howard Federoff(Executive Officer, Director)Nick Manusos(Executive Officer, Director)Martin Ostrowski(Executive Officer)Jonathan Yeh(Director)
BoardJeff Goater(Director)in
Board seatDavid Fallace· per SEC Form D · $81.8M raise · filed Mar 2024
Co-investorsThe Column Group
Unlocking post-translational protein modification using chemical biology and computational approaches to develop drugs for previously undruggable oncology targets.
BiotechCambridge, US
Xu Wu(Director)
BoardSeth Lieblich(Director)inMichael Aberman(Director)Drew King(Executive Officer)Milenko Cicmil(Executive Officer, Director)
Board seatDavid Fallace· per SEC Form D
Discovering and developing therapeutic molecules derived from exercise to treat neurodegenerative diseases including Parkinson's.
Aevum develops therapeutic molecules derived from exercise to treat disease.
BiotechLongevity
Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.
BiotechHealthtechCambridge, US
Co-investorsCatalio Capital Management, LPVivo CapitalCatalio Capital ManagementNovo HoldingsThird Rock Ventures
Engineering cancer medicines that conditionally assemble in the tumor microenvironment across multiple therapeutic modalities.
Advancing off-the-shelf dopamine neuron replacement therapies as a disease-modifying treatment for neurological disorders like Parkinson's disease.
Kenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for neurological conditions such as Parkinson's disease.
BiotechHealthtechMedical Devices
Co-investorsThe Column Group
Developing precision biologics to treat autoimmune and inflammatory diseases with exceptional safety profile.
Kobuk Therapeutics is developing a biologics platform aimed at treating autoimmune diseases by resetting the immune system to a healthy state while preserving protective immunity.
BiotechHealthtech
Permeasis Therapeutics is developing a Membrane Translocation Domain (MTD) platform that enables intracellular delivery of proteins and other large therapeutic macromolecules to the cytosol and intracellular compartments.
BiotechDeep TechBoston, US
Providing a virtual-first care delivery platform with integrated primary care, behavioral health, urgent care, and supplemental benefits.
Recuro is a virtual-first digital health platform that provides primary care, behavioral health, urgent care, and supplemental benefits (pharmacy, care management, advocacy) to patients, employers, health plans, and providers.
Digital HealthHealthtechSaaSRichardson, US
Michael Brombach(Chief Executive Officer and Co-Founder)Michael Gorton(Chief Executive Officer)inDr. Kate Sowerwine(Chief Medical Officer)John Halsey(Director)Kris Engskov(Director)William Paiva(Director)
Co-investors1843 Capital4D CapitalARCH Venture PartnersCortado VenturesGlobal Insurance Accelerator
Tasca develops new cancer medicines using a drug discovery platform that identifies and maps novel lipid-binding pockets on proteins.
BiotechHealthtech
Tortugas Neuro is a neuroscience drug development company focused on the neurology and neuropsychiatry space, working to advance clinical-stage therapies for brain health.
BiotechHealthtech
Co-investorsAN Venture PartnersThe Column Group
Developing therapeutics for neurological diseases with high unmet need using translational approaches.
US-based neuroscience company and AN Venture Partners portfolio investment.
Co-investorsAN Venture Partners
Triton Therapeutics is a clinical-stage biotechnology company developing first-in-class medicines for autoimmune and fibrotic diseases.
BiotechHealthtechStamford, US
BoardAnnie Mitsak(Director)Timothy Shannon(Director)Elena Grigoryeva(Director)Paul Fonteyne(Executive Officer, Director)
Co-investorsCanaan Partners
Developing a novel antibody-enzyme fusion to target tumors and trigger immune response through fusion protein technology.
XenImmune is an immuno-oncology company developing first-in-class molecules that apply the biology of organ transplant hyperacute rejection to fight cancer by "painting" tumors with foreign blood groups to trigger anti-tumor immune responses.
BiotechHealthtechCambridge, US
Crosslink develops a modular biologic domain that assembles therapeutics within tumors to improve tumor-specific targeting and activity.
BiotechHealthtech
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.